(Q37507490)

20 August 2017

1 reference

title

Treatment of focal segmental glomerulosclerosis with immunophilin modulation: when did we stop thinking about pathogenesis? (English)

1 reference

focal segmental glomerulosclerosis

20 August 2017

0 references

1 reference

Alain Y Meyrier

1

1 reference

20 August 2017

language of work or name

English

0 references

publication date

3 June 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

76

1 reference

20 August 2017

issue

5

1 reference

20 August 2017

page(s)

487-491

1 reference

Pathologic classification of focal segmental glomerulosclerosis: a working proposal

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Urinary CD80 excretion increases in idiopathic minimal-change disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

An update on the treatment options for focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Direct effects of dexamethasone on human podocytes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Proteinuria and immunity--an overstated relationship?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Pathogenesis of lipoid nephrosis: a disorder of T-cell function

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Treatment of glomerular disease with cyclosporin A.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Effect of febrile plasma, typhoid vaccine and nitrogen mustard on renal manifestations of human glomerulonephritis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

A case of unfulfilled expectations. Cytokines in idiopathic minimal lesion nephrotic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Cyclosporine prevents the increase in glomerular albumin permeability caused by serum from patients with focal segmental glomerular sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Cyclosporine protects glomeruli from FSGS factor via an increase in glomerular cAMP

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Signaling to gene expression: calcium, calcineurin and NFAT

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Rituximab and nephrotic syndrome: a new therapeutic hope?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Effects of cyclosporin A on glomerular barrier function in the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Cyclosporine a slows the progressive renal disease of alport syndrome (X-linked hereditary nephritis): results from a canine model

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Glomerular endothelial glycocalyx constitutes a barrier to protein permeability

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Focal and segmental glomerulosclerosis: definition and relevance of a partial remission

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

2007 Young Investigator Award: TRP'ing into a new era for glomerular disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Recurrent focal glomerulosclerosis: natural history and response to therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Transmission of glomerular permeability factor from a mother to her child

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Management of glomerular proteinuria: a commentary

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Effects of steroids in focal segmental glomerulosclerosis in a predominantly African-American population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Presenting features and short-term outcome according to pathologic variant in childhood primary focal segmental glomerulosclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.204

7 January 2021

Identifiers

DOI

10.1038/KI.2009.204

1 reference

20 August 2017

1 reference